Physician profile
John Dean Ibrahim
NPI 1669555470
$15,544.89
in general payments reported to CMS, 2019-2025
52 companies · $2,311 in 2025
The $2,311 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,431 · 2020: $1,577 · 2021: $3,066 · 2022: $3,556 · 2023: $1,800 · 2024: $1,804 · 2025: $2,311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,897 · Education: $18.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,896.52 |
| Education | $18.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,363.42 | 2019-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $1,355.46 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Corcept Therapeutics | $1,291.33 | 2024-2025 | Korlym |
| Glaxosmithkline, LLC. | $1,066.35 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Esperion Therapeutics, INC. | $1,042.29 | 2020-2025 | Nexletol |
| Lilly USA, LLC | $962.44 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $751.26 | 2019-2025 | |
| Amgen INC. | $706.25 | 2019-2025 | Repatha, Otezla, Tavneos |
| Bayer Healthcare Pharmaceuticals INC. | $701.94 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $663.66 | 2019-2025 | Jardiance |
| Abbott Laboratories | $406.94 | 2021-2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Amarin Pharma, INC. | $387.39 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $332.82 | 2019-2023 | Belsomra |
| Bausch Health US, LLC | $320.20 | 2022-2025 | Aplenzin |
| Biohaven Pharmaceutical Holding Company LTD. | $291.51 | 2022 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ibrahim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.